Issue 38 - Oct 14, 2016
  • Davidson Moves to Seattle Cancer Consortium

    Nancy Davidson was named executive director of the Fred Hutchinson/University of Washington Cancer Consortium effective Dec. 1. For nearly eight years, Davidson has served as director of the University of Pittsburgh Cancer Institute.

    In the new role, Davidson, will coordinate cancer treatment, clinical and translational research programs of consortium members Fred Hutch, UW School of Medicine, Seattle Children’s and Seattle Cancer Care Alliance, the cancer treatment arm of Fred Hutch, UW Medicine and Seattle Children’s.

  • Where is the FY18 Bypass Budget? 

    Cancer Groups Want to Know

    The NCI Bypass Budget was expected to be made public on Oct. 6.

    Alas, this didn’t happen; why didn’t it?

    America’s top cancer groups would like to know, and theirs is not idle curiosity. The NCI Bypass Budget is an important, unique authority established by the National Cancer Act of 1971. 

  • Guest Editorial

    Goodman: Too Many PD-1 Trials for Adults, Too Few for Children

    Kudos to The Cancer Letter’s report on the 803 PD-1 or PD-L1 trials. As Rick Pazdur noted, that is just too many resources chasing the same idea for adult cancer studies.  

    Alas, as of Friday, Oct. 7, clinicaltrials.gov shows only two open trials for a PD-1 or PD-L1 trial for patients 0 to 17 years of age, and both are monotherapies. There are no listed combination trials that are open and accept kids. There are no PD-L2 trials listed that accept kids.

  • In Brief

    • Adrian Lee named director of the Institute for Precision Medicine
    • Kwok-Kin Wong named chief of hematology and medical oncology at the Perlmutter Cancer Center at NYU Langone Medical Center
    • Yanis Boumber joins the Department of Thoracic Medical Oncology and the Molecular Therapeutics Program at Fox Chase Cancer Center
    • Stanley Marks honored through the establishment of the Stanley M. Marks–OHA Endowed Chair in Hematology/Oncology Leadership
    • Robert Figlin appointed deputy director of the Integrated Oncology Service Line at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute
    • Suresh Ramalingam selected to hold the Roberto C. Goizueta Distinguished Chair for Cancer Research
    • Jacqueline Corrigan-Curay selected as permanent director of FDA Office of Medical Policy at the Center for Drug Evaluation and Research
    • Ann Richmond wins the 2016 William S. Middleton Award
    • Marc Benioff and wife Lynne give $20 million toward construction of the Lawrence J. Ellison Institute for Transformative Medicine of University of Southern California
    • Boris Lushniak named dean of the University of Maryland School of Public Health
    • Southern Research Institute awarded five-year IDIQ contract from NCI
    • Dr. Susan Love Research Foundation receives $3 million NCI grant 
    • NIH expands a five-year funding award to The Scripps Research Institute from $120 million to $207 million
    • Mount Sinai receives a $10 million grant from NCI
    • The University of Michigan Comprehensive Cancer Center and Tempus partner to bring MI-ONCOSEQ to patients and healthcare providers
    • Merck KGaA announces the recipients of the 2016 Grant for Oncology Innovation
    • Research!America announces 2017 Advocacy Award winners
  • Drugs and Targets

    • Genentech receives second Breakthrough Therapy Designation from FDA for Alecensa

    • Gamida Cell says FDA has granted Breakthrough Therapy Designation to NiCord
    • Foundation Medicine, Inc. announces new clinical markers added to FoundationOne and FoundationOne Heme products
    • Abbvie said Health Canada issued a Notice of Compliance with Conditions for Venclexta
    • The US Oncology Network selects Myriad Genetics as its preferred provider laboratory for hereditary cancer testing
  • Funding Opportunities

    Pershing Square Sohn Cancer Research Alliance is accepting applications for its Prize for Young Investigators in Cancer Research.

    The prize of $200,000 per year for up to three years is awarded annually to at least five New York City-based scientists, enabling them to continue to pursue explorative and high-risk/high-reward research at a stage when traditional funding is lacking.

Issue 37 - Oct 7, 2016
Issue 36 - Sep 30, 2016
  • Two Gigantic Health Systems Integrate Cancer Data to Bring Precision Medicine to Community Care

    By Matthew Bin Han Ong

    Two of the nation’s biggest nonprofit health systems—Dignity Health and Catholic Health Initiatives—launched a precision medicine program that has the potential to create the largest collection of clinical cancer data ever compiled by a single organization.

    Together, Dignity and CHI, based in San Francisco and Englewood, Colo., respectively, operate nearly 150 hospitals and care centers across the U.S. Both rank in the top five largest nonprofit hospital systems.

  • NCI Suspends Frederick Lab Re-Competition Citing Moonshot, Zika and Ebola Research

    NCI has suspended re-competition of the the $400 million-a-year operations and technical support contract for the Frederick National Laboratory for Cancer Research.

    A brief notice of suspension was posted on the Federal Business Opportunities website at 4:06 p.m. Friday, Sept. 30, in the final business hours of the final day of the fiscal year.

  • Conversation with The Cancer Letter

    NCI’s Care Delivery Research Program Seeks to Involve Scientists from Other Fields

    Paul Jacobsen was named associate director of the NCI Division of Cancer Control and Population Science Healthcare Delivery Research Program. Jacobsen says he hopes his joining the institute signals to the scientific community the strength of the institute’s commitment to healthcare delivery research.

    “The use of ‘healthcare delivery research’ in the name of the program was intended to signal an interest in adding to the richness of traditional health services research by involving scientists from other fields whose work would be applicable to cancer care delivery settings,” said Jacobsen, who was most recently the associate center director for population science at the Moffitt Cancer Center.

  • Continuing Resolution Funds Zika, But Not Cancer or Biden’s Moonshot

    A continuing resolution passed Congress passed Sept. 28 will avoid a government shutdown and fund federal agencies through Dec. 9.

    This legislation comes two days before the government’s current funding was due to expire, at midnight Sept. 30. This would have closed all nonessential parts of the government, including NIH.

  • In Brief

    • University of Michigan Cancer Center appoints research leadership team
    • Richard Goldberg retires from Ohio State Cancer Center
    • Peter Schultz receives international Heinrich Wieland Prize
    • Lisa Kennedy Sheldon named chief clinical officer of Oncology Nursing Society
    • Christopher Heery named chief medical officer of Bavarian Nordic A/S
    • Timothy Kuzel named division chief at Rush University Medical Center
    • Morphotek Inc. enters sponsored research agreement with Fox Chase Cancer Center
    • Tempus partners with Northwestern’s Lurie Cancer Center on precision medicine partnership
  • Drugs and Targets

    • Multiple Myeloma Research Foundation contributes data to NCI Genomic Data Commons
    • Janssen submits supplemental FDA New Drug Application for ibrutinib
    • Boehringer Ingelheim and ViraTherapeutics to collaborate on oncolytic virus therapy platform
    • Genomics England Partners with GenomOncology on 100,000 Genomes Project
    • Pronai Therapeutics obtains exclusive license to develop and commercialize PNT737
    • Prix Galien Foundation announces “Discovery of the Decade” nominees